NOT-DK-18-008: Clarification on the Number of Applications Allowed Per Organization for RFA-DK-17-018: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 Clinical Trial Optional)

Clarification on the Number of Applications Allowed Per Organization for RFA-DK-17-018: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 Clinical Trial Optional)

Notice Number: NOT-DK-18-008

Key Dates
Release Date: January 11, 2018

Related Announcements
RFA-DK-17-018

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The purpose of this Notice is to inform the scientific community applicant organizations may submit only one application.

Section III. 3 Additional Information of Eligibility

Currently:
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

Now reads:
Number of Applications
Applicant organizations may submit one application.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Robert W. Karp, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: (301) 451-8875
Email: karpr@mail.nih.gov